Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE

Empery Asset Management LP lessened its stake in Satellos Bioscience Inc. (NASDAQ:MSLE) by 53.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,100 shares of the company’s stock after selling 123,000 shares during the quarter. Satellos Bioscience accounts for about 1.0% of Empery Asset Management LP’s investment portfolio, making the stock its 15th biggest holding. Empery Asset Management LP’s holdings in Satellos Bioscience were worth $832,703,000 as of its most recent filing with the Securities & Exchange Commission.

Analyst Ratings Changes

MSLE has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Satellos Bioscience in a report on Monday, August 17th. Canaccord Genuity Group raised shares of Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Guggenheim began coverage on Satellos Bioscience in a report on Tuesday, April 28th. They set a “buy” rating and a $23.00 target price for the company. Finally, Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.75.

Satellos Bioscience Price Performance

NASDAQ MSLE opened at $10.01 on Friday. The company has a market cap of $208.61 million, a PE ratio of -5.21 and a beta of 1.51. The company has a 50 day moving average price of $8.61. Satellos Bioscience Inc. has a 52 week low of $5.14 and a 52 week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). Sell-side analysts forecast that Satellos Bioscience Inc. will post -2.08 earnings per share for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.